Ma Dou Ling
Aristolochia debilis Sieb. et Zucc.; Aristolochia contorta Bge.
Also known as: Aristolochia Fruit(English) 马兜铃(Chinese)
Ma Tou Ling
Updated October 14, 2026 · Not yet clinically reviewed
Safety at a glance
Aristolochic acid — prescription-only in China since 2004 (国食药监注[2004]379号); not carried into the Chinese Pharmacopoeia 2020 (its earlier standard still applies)
Graded severe in our catalogue
6 recorded drug interactions, 6 major or contraindicated
Contraindications or side effects are listed
Traditional Chinese Medicine
- Category
- transforming phlegm
- Temperature
- Cold
- Taste
- Bitter,Pungent
- Channels
- Lung,Large Intestine
Functions
Clears Lung Heat; Descends Lung Qi and Stops Cough; Resolves Phlegm and Stops Cough; Calms Wheezing; Clears the Large Intestine and treats hemorrhoids
Traditional uses
Ma Dou Ling (birthwort fruit, Aristolochia fruit) is a cold herb that descends Lung Qi, clears Lung Heat, and calms wheezing. It addresses hot-type cough and asthma with yellow phlegm, as well as hemorrhoids with bleeding from Heat in the Large Intestine. Due to the presence of aristolochic acid — a compound with known nephrotoxicity — this herb is subject to regulatory restrictions in many countries and should only be used under medical supervision with strict dosage controls.
Western herbalism
Properties: expectorant
Formulas using this herb
2 of 2 formulas
- Bu Fei E Jiao Tang 补肺阿胶汤 · 6.00000g · deputy
- Shen Xian Huo Ming Tang · 9.00000g
Botanical
Aristolochia debilis (and the related A. contorta) are slender perennial twining vines in the family Aristolochiaceae, native to China, Korea, and Japan. The stems are herbaceous to weakly woody and climb to 1–2 m; the alternate leaves are triangular-ovate to halberd-shaped with cordate bases. Flowers are solitary, axillary, and bilaterally symmetrical with a curved trumpet-shaped perianth tube about 3 cm long, yellowish-green with purple-brown veining, functioning as a fly trap for pollination. The fruit (Ma Dou Ling) is a six-valved pendulous capsule 3–6 cm long, splitting from the apex into six sections that resemble a hanging bell or horse bell — the source of the Chinese name. In TCM the dried ripe fruit is bitter and cold, clearing lung-heat and arresting cough. The genus contains nephrotoxic and carcinogenic aristolochic acids; its sale is restricted or banned in many countries.
- Family
- Aristolochiaceae
- Pharmaceutical name
- Fructus Aristolochiae
- Parts used
- fruit
- Plant type
- vine
Constituents
Aristolochic acid I
Nitrophenanthrene carboxylic acid · Within the capsule it is not evenly spread: quantitation of outer pericarp, inner pericarp, septum and seed of Aristolochia contorta fruit by UHPLC-QqQ-MS found aristolochic acid I and II accumulating exclusively in the seeds
The principal nephrotoxin and carcinogen of the genus. It is nitroreduced, chiefly by cytosolic NAD(P)H:quinone oxidoreductase 1 and by CYP1A1 and CYP1A2 under low oxygen, to a cyclic nitrenium ion that binds deoxyadenosine to give aristolactam-DNA adducts. Those adducts persist for decades in renal cortex and produce the A to T transversion signature seen in upper tract urothelial tumours. The organ distribution matters here: a deseeded pericarp preparation and a whole-fruit preparation are not the same exposure.
Aristolochic acid II
Nitrophenanthrene carboxylic acid · Also confined to the seeds of the Aristolochia contorta fruit in the same part-by-part analysis
Bioactivated by the same nitroreduction route as aristolochic acid I and likewise DNA-adduct forming. It lacks the methoxy group that aristolochic acid I carries, so it is not available for the CYP1A-mediated O-demethylation that detoxifies aristolochic acid I.
Aristolochic acid IVa
Nitrophenanthrene carboxylic acid · Higher than aristolochic acid VIIa in Aristolochia contorta fruit; measured across 11 batches of A. contorta and 15 batches of A. debilis fruit
Chemically it is one of the aristolochic acid analogues of the fruit. Its practical use is as an identity marker: the ratio of aristolochic acid IVa to VIIa runs one way in A. contorta fruit and the other way in A. debilis fruit, and on that criterion all 33 commercial Madouling samples collected across 12 Chinese provinces proved to be A. contorta, not A. debilis.
Aristolochic acid VIIa
Nitrophenanthrene carboxylic acid · Higher than aristolochic acid IVa in Aristolochia debilis fruit, the reverse of the A. contorta pattern
The second half of the species-discriminating pair. Present in the fruit of both official source plants.
Aristolochic acid IIIa
Nitrophenanthrene carboxylic acid · One of the seven aristolochic acid analogues quantified in Aristolochiae Fructus by validated HPLC
A hydroxylated analogue of the series. Analogues beyond aristolochic acid I and II are not routinely measured in regulatory screening, so an assay reporting only aristolochic acid I understates the total analogue load of the fruit.
Aristolactam I
Phenanthrene lactam alkaloid · One of five aristolactams identified across the four fruit parts; quantified alongside aristolactam II in both source species
The reduced end-product of aristolochic acid metabolism and also a native constituent of the fruit. Aristolactam-DNA adducts in renal cortex are the biomarker used to prove aristolochic acid exposure in patients years after the herb was taken.
Aristolactam II
Phenanthrene lactam alkaloid · Quantified with aristolactam I in 11 batches of A. contorta and 15 batches of A. debilis fruit
Companion aristolactam of the fruit, formed from aristolochic acid II by the same nitroreduction.
Drug interactions
Any nephrotoxic drug (NSAIDs, aminoglycosides, cisplatin, calcineurin inhibitors, iodinated contrast media)
Major · Severe - irreversible interstitial fibrosis, end-stage renal failure and urothelial carcinoma · Evidence level: Established
The aristolochic acids of this fruit cause a progressive hypocellular interstitial fibrosis of the renal cortex and upper tract urothelial carcinoma. The lesions are irreversible, no effective treatment for either exists, and there is no threshold dose below which the DNA adducts are not formed. Any co-administered nephrotoxin adds insult to a kidney already being scarred, and falling glomerular filtration in turn raises exposure to renally cleared drugs.
Clinical note: There is no safe combination because there is no safe dose of the herb. Do not dispense it. In a patient with a past exposure history, avoid additional nephrotoxins, monitor renal function, and refer for urothelial surveillance.
CYP1A1 and CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, cimetidine)
Major · Severe - increased DNA adduct burden from a given exposure · Evidence level: Probable
CYP1A1 and CYP1A2 sit on both sides of aristolochic acid I metabolism. Under aerobic conditions they O-demethylate it to 8-hydroxyaristolochic acid, a detoxication; under low oxygen they nitroreduce it and add to the adduct burden. Which reaction dominates in vivo was settled in rats: inducing CYP1A1 and 1A2 with Sudan I before dosing lowered aristolochic acid I DNA adducts in liver, kidney and lung by diverting the compound into O-demethylation. Blocking those enzymes should therefore push the balance the other way. Human CYP1A2 varies more than 60-fold between individuals, which is one reason exposed patients do not all develop disease.
Clinical note: Relevant to counselling a patient with past exposure rather than to prescribing: nothing about enzyme status makes the herb acceptable to give. Do not present CYP1A induction as a protective strategy.
Inorganic arsenic (contaminated well water, arsenic trioxide, arsenic-accumulating seaweeds)
Major · Severe - additive increase in upper tract urothelial carcinoma risk · Evidence level: Established
Two Taiwanese cohorts, one hospital-based with 89 patients and one population-based with 2,921 cases and 11,684 controls, graded arsenic exposure from well water and arseniasis-related disease and measured aristolochic acid exposure by aristolactam-DNA adducts in renal cortex, A to T TP53 mutations and prescription records. Logistic regression showed the two carcinogens act additively on upper tract urothelial carcinoma risk. Aristolactam-DNA adducts were present in over 90 per cent of the hospital patients, whether or not they lived in an arsenic-endemic area.
Clinical note: Take a water-source and dietary-seaweed history in any patient with documented or suspected aristolochic acid exposure, because the two exposures compound rather than compete.
Other aristolochic acid-containing herbs (Xi Xin, Guan Mu Tong, Guang Fang Ji, Tian Xian Teng)
Major · Severe - cumulative dose across a prescription · Evidence level: Established
Risk tracks cumulative aristolochic acid dose, and formulas routinely stack several sources. In a 200,000-patient sample of Taiwan National Health Insurance data covering 1997 to 2003, 78,644 patients received aristolochic-acid-containing products across 526,867 prescriptions, and about 7 per cent exceeded a cumulative 100 g of Xi Xin, Mu Tong or this fruit, Fructus Aristolochiae. Tian Xian Teng is the stem of the same two plants that supply this fruit, so prescribing both doubles a single botanical exposure without appearing to.
Clinical note: Screen the whole formula, not the single herb. Treat Tian Xian Teng and this drug as one exposure, since they come from the same plants.
Honey-processed preparation (Mi Zhi Ma Dou Ling)
Major · Severe - a preparation widely assumed to be detoxified is not · Evidence level: Probable
The honey-roasted form is the usual dispensing form of this fruit, and processing is often taken to have made it safe. Review of detoxication techniques for aristolochic-acid-containing drugs finds that honey and alkaline-salt processing are the two methods used in practice, that alkaline-salt processing removes far more of the acids because they are weak acids, and that no processing method removes them completely. Reduction is not elimination, and the carcinogenic endpoint has no threshold.
Clinical note: Do not treat honey-processing, decoction or combination with other herbs as making this drug safe to give. None of the processing evidence extends to a human safety claim.
Mu Tong, Fang Ji and other same-name or look-alike drugs
Major · Severe - unlabelled aristolochic acid exposure · Evidence level: Probable
Aristolochic acid injuries have repeatedly arisen from substitution rather than from deliberate prescribing, the Belgian slimming-clinic nephropathy of 1993 being the founding example, in which Aristolochia material reached patients in place of a Stephania. Chinese herbal products may contain aristolochic acid or be adulterated with herbs suspected of containing it, and the commercial supply of this fruit itself is not what the pharmacopoeial listing implies: all 33 commercial Madouling samples collected from 12 Chinese provinces tested to Aristolochia contorta, although both A. contorta and A. debilis are official source plants.
Clinical note: Authenticate to species by chemical or molecular means, not by the label. Unexplained interstitial nephritis in a herbal-medicine user warrants an aristolochic acid exposure work-up even when no Aristolochia was knowingly given.
Dosage
| Form | Amount | Frequency | Notes |
|---|---|---|---|
| not recommended | Not established — should not be dispensed | Daily | **This drug should not be dispensed.** Ma Dou Ling is Aristolochia debilis. All Aristolochia species contain aristolochic acid, which causes irreversible aristolochic acid nephropathy and urothelial carcinoma, and is an IARC Group 1 human carcinogen. China removed the Aristolochia drugs from the Pharmacopoeia; 马兜铃 has no current ChP monograph and no defensible dose. Same basis as zhu-sha-lian. |
Evidence
Study design on record, not certainty of outcome.
- Observational / case report
- 3
- In vitro / animal
- 2
Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma
Jhuang JR, Chiu PC, Hsieh TC, Chen CH, Pu YS, Lee WC · Frontiers in Public Health · 2023 · cohort
Observational / case report · Not yet verified
Population-based cohort of 752,232 Taiwanese aged 40 to 79, linking insurance, cancer registry and mortality data. Cumulative aristolochic acid dose was 1-150 mg in 27.6 per cent and above 150 mg in 4.1 per cent; 1,147 developed upper tract urothelial carcinoma between 2005 and 2016. Measured latency was 7 to 9 years and varied with age, sex and dose, and risk fell after the Taiwanese ban. The practical point is that the cancer appears the better part of a decade after the herb was taken, so a patient who feels well after a course is not thereby unharmed.
Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium
Chen CH, Grollman AP, Huang CY, Shun CT, Sidorenko VS, Hashimoto K, Moriya M, Turesky RJ, Yun BH, Tsai K, Wu S, Chuang PY, Tang CH, Yang WH, Tzai TS, Tsai YS, Dickman KG, Pu YS · Cancer Epidemiology, Biomarkers and Prevention · 2021 · cohort
Observational / case report · Not yet verified
Paired hospital cohort of 89 patients and population cohort of 2,921 cases against 11,684 controls. Aristolactam-DNA adducts were found in over 90 per cent of the hospital patients, showing how widespread the exposure was, and A to T TP53 mutations were present in a fifth to nearly half of them depending on arsenic grade. Aristolochic acid and arsenic exposure combined additively to raise upper tract urothelial carcinoma risk.
Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003
Hsieh SC, Lin IH, Tseng WL, Lee CH, Wang JD · Chinese Medicine · 2008 · cohort
Observational / case report · Not yet verified
Longitudinal analysis of a random 200,000-patient sample of Taiwanese insurance data. 78,644 patients received aristolochic-acid-containing products in 526,867 prescriptions across 1,218 licensed items; around 7 per cent exceeded a cumulative 100 g of Xi Xin, Mu Tong or Fructus Aristolochiae, this drug. Prescriptions clustered in respiratory and musculoskeletal complaints, which is precisely where this fruit was used.
Bioactivation versus Detoxication of the Urothelial Carcinogen Aristolochic Acid I by Human Cytochrome P450 1A1 and 1A2
Stiborová M, Levová K, Bárta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Arlt VM · Toxicological Sciences · 2012 · animal
In vitro / animal · Not yet verified
CYP1A-humanised mouse lines, human and mouse liver microsomes and recombinant enzymes. Human CYP1A1 and 1A2 both reductively activate aristolochic acid I to the DNA-adduct-forming species and oxidatively detoxify it to 8-hydroxyaristolochic acid, with tissue oxygen concentration tipping the balance. Because human CYP1A2 varies more than 60-fold across the population, individual susceptibility to a given exposure varies too.
Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo
Dračínská H, Bárta F, Levová K, Hudecová A, Moserová M, Schmeiser HH, Kopka K, Frei E, Arlt VM, Stiborová M · Toxicology · 2016 · animal
In vitro / animal · Verified
Rats given aristolochic acid I alone or after pretreatment with the CYP1A1/2 inducer Sudan I. Adduct levels measured by 32P-postlabelling were lower in liver, kidney and lung after induction, because more of the compound was diverted into O-demethylation to 8-hydroxyaristolochic acid. In the intact animal the oxidative detoxication limb of CYP1A1/2 therefore dominates over the nitroreductive one.
Safety
Toxicity: severe
Contraindications
Dosage should be not too large. Its use is prohibited in patients with cough and panting due to deficiency-cold or loose stool due to spleen deficiency, or pregnant women, infants and those with renal dysfunction.
Source: Xi S, Gong Y. Essentials of Chinese Materia Medica and Medical Formulas. Academic Press/Elsevier, 2017, pp. 282–289.
⚠ Rule-based cautions
These entries come from the deterministic rule tables that gate Verscienta's formula tools: classical pair prohibitions, pregnancy and lactation contraindications, dose ceilings, and drugs outside the Chinese Pharmacopoeia. The botanical-genus entries are different: advisory notes are not part of the safety screen; the Aristolochia genus check is.
Chinese Pharmacopoeia status
prescription-only in China since 2004 (国食药监注[2004]379号); not carried into the Chinese Pharmacopoeia 2020 (its earlier standard still applies)
restricted to prescription use with a mandatory aristolochic-acid label warning (国食药监注[2004]379号, items 六、七); in ChP 2015 (一部 p.51) but not carried into ChP 2020 — under 国家药监局公告2020年第80号 its earlier standard still applies
国家食品药品监督管理局 国食药监注[2004]379号《关于加强广防己等6种药材及其制剂监督管理的通知》(2004-08-05);《中国药典》2015年版一部 — 马兜铃 (p.51), 【注意】;国家药监局公告2020年第80号《关于实施2020年版〈中华人民共和国药典〉有关事宜的公告》(2020-07-03): 本版《中国药典》未收载的,仍执行相应历版药典、局(部)颁标准
Pending clinical review.
⚠ Toxicity
Compounds: Aristolochic acids I and II (nitrophenanthrene carboxylic acids), nephrotoxic and carcinogenic (IARC Group 1).
Cultural and historical
Lei Gong Pao Zhi Lun · Southern and Northern dynasties, c. 5th century CE
Xin Xiu Ben Cao · Tang dynasty, 659 CE
Ben Cao Gang Mu · Ming dynasty, 1596
References
- Mao WW, Gao W, Liang ZT, Li P, Zhao ZZ, Li HJ. Characterization and quantitation of aristolochic acid analogs in different parts of Aristolochiae Fructus, using UHPLC-Q/TOF-MS and UHPLC-QqQ-MS. Chinese Journal of Natural Medicines. 2017 doi:10.1016/s1875-5364(17)30060-2
- Xu YQ, Li XW, Liu GX, Wang X, Shang MY, Li XM, Cai SQ. Comparative study of the contents of analogues of aristolochic acid in two kinds of Aristolochiae Fructus by high-performance liquid chromatography. Journal of Natural Medicines. 2013 doi:10.1007/s11418-012-0664-9
- Han J, Xian Z, Zhang Y, Liu J, Liang A. Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms. Frontiers in Pharmacology. 2019 doi:10.3389/fphar.2019.00648
- Fan Y, Li Z, Xi J. Recent developments in detoxication techniques for aristolochic acid-containing traditional Chinese medicines. RSC Advances. 2020 doi:10.1039/c9ra08327h
- Yue L, Yang K, Jiang F, Dong S, Yang K, Zhu D. Chemical profiling of principle active and toxic constituents in herbs containing aristolochic acids. Chinese Herbal Medicines. 2024 doi:10.1016/j.chmed.2023.02.008